Drugs / A6
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02046928 | Feb 2014 → Nov 2015 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Ångstrom Pharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00083928 | May 2004 → Feb 2006 | ovarian carcinoma, primary peritoneal carcinoma | Ångstrom Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Å6 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00083928 ↗ |
| Modality | Peptide | “A6, a CD44 Binding Peptide” NCT02046928 ↗ |
| Route | Subcutaneous | “Å6 subcutaneous injection” NCT00083928 ↗ |
| Target | CD44 | “A6, a CD44 Binding Peptide” NCT02046928 ↗ |